A. Craig Lockhart

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial.

K. Kelly, G. Weiss, J. Infante, 2015 .